Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.

Marshall DA, Deal K, Bombard Y, Leighl N, MacDonald KV, Trudeau M.

BMJ Open. 2016 Jun 2;6(6):e010981. doi: 10.1136/bmjopen-2015-010981. Erratum in: BMJ Open. 2016;6(6):e010981corr1.

2.

Chromatin Regulators as a Guide for Cancer Treatment Choice.

Gurard-Levin ZA, Wilson LO, Pancaldi V, Postel-Vinay S, Sousa FG, Reyes C, Marangoni E, Gentien D, Valencia A, Pommier Y, Cottu P, Almouzni G.

Mol Cancer Ther. 2016 Jul;15(7):1768-77. doi: 10.1158/1535-7163.MCT-15-1008.

PMID:
27196757
3.

Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation.

Huh JW, Kim SC, Sohn I, Jung SH, Kim HC.

Oncotarget. 2016 Mar 29;7(13):16338-48. doi: 10.18632/oncotarget.7488.

4.

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Mouttet D, Laé M, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Vincent-Salomon A, Rouzier R, Sigal-Zafrani B, Sastre-Garau X, Reyal F.

PLoS One. 2016 Feb 1;11(2):e0146474. doi: 10.1371/journal.pone.0146474.

5.

Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures.

Modelska A, Quattrone A, Re A.

Brief Bioinform. 2015 Nov;16(6):1000-7. doi: 10.1093/bib/bbv013. Review.

6.

The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.

Issa AM, Chaudhari VS, Marchant GE.

Expert Rev Mol Diagn. 2015 Feb;15(2):277-86. doi: 10.1586/14737159.2015.983476. Review.

7.

An argument for mechanism-based statistical inference in cancer.

Geman D, Ochs M, Price ND, Tomasetti C, Younes L.

Hum Genet. 2015 May;134(5):479-95. doi: 10.1007/s00439-014-1501-x. Review.

8.

Understanding patient and provider perceptions and expectations of genomic medicine.

Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB.

J Surg Oncol. 2015 Jan;111(1):9-17. doi: 10.1002/jso.23712. Review.

9.

Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.

Farr A, Wuerstlein R, Heiduschka A, Singer CF, Harbeck N.

Rev Obstet Gynecol. 2013;6(3-4):165-73.

10.

Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.

Pant S, Weiner R, Marton MJ.

Front Oncol. 2014 Apr 17;4:78. doi: 10.3389/fonc.2014.00078. Review.

11.
12.

Genomics, personalized medicine, and pediatrics.

Feero WG, Guttmacher AE.

Acad Pediatr. 2014 Jan-Feb;14(1):14-22. doi: 10.1016/j.acap.2013.06.008. Review.

13.

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.

Carlson JJ, Roth JA.

Breast Cancer Res Treat. 2013 Aug;141(1):13-22. doi: 10.1007/s10549-013-2666-z. Review. Erratum in: Breast Cancer Res Treat. 2014 Jul;146(1):233.

14.

A simple and reproducible breast cancer prognostic test.

Marchionni L, Afsari B, Geman D, Leek JT.

BMC Genomics. 2013 May 17;14:336. doi: 10.1186/1471-2164-14-336.

15.

Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.

Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J, Friend SH, Stolovitzky G, Aparicio S, Caldas C, Børresen-Dale AL.

Sci Transl Med. 2013 Apr 17;5(181):181re1. doi: 10.1126/scitranslmed.3006112.

16.

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.

Varga Z, Sinn P, Fritzsche F, von Hochstetter A, Noske A, Schraml P, Tausch C, Trojan A, Moch H.

PLoS One. 2013;8(3):e58483. doi: 10.1371/journal.pone.0058483. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/f715f38e-7aee-4d2b-8bbf-da0411dc6ef3.

17.

Barriers to the use of personalized medicine in breast cancer.

Weldon CB, Trosman JR, Gradishar WJ, Benson AB 3rd, Schink JC.

J Oncol Pract. 2012 Jul;8(4):e24-31. doi: 10.1200/JOP.2011.000448.

18.

Computational medicine: translating models to clinical care.

Winslow RL, Trayanova N, Geman D, Miller MI.

Sci Transl Med. 2012 Oct 31;4(158):158rv11. doi: 10.1126/scitranslmed.3003528.

20.

Fluorescent polymer-based post-translational differentiation and subtyping of breast cancer cells.

Scott MD, Dutta R, Haldar MK, Wagh A, Gustad TR, Law B, Friesner DL, Mallik S.

Analyst. 2012 Dec 7;137(23):5487-90. doi: 10.1039/c2an35877h.

Supplemental Content

Support Center